Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse
暂无分享,去创建一个
D. Groheux | M. Espié | E. Hindié | L. Vercellino | A. de Roquancourt | M. Marty | S. Giacchetti | M. Delord | A. Hamy | N. Bérenger
[1] A. Rossi,et al. Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.
[2] D. Groheux,et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Marc Espié,et al. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[4] S. Rodenhuis,et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[6] M. Espié,et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients , 2010, Breast Cancer Research and Treatment.
[7] D. Mankoff,et al. Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer , 2010, Clinical Cancer Research.
[8] E. Perez,et al. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.
[9] M. Espié,et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. , 2010, The oncologist.
[10] Winfried Brenner,et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Debra L Winkeljohn. Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.
[12] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Alavi,et al. Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parameters , 2008, Cancer.
[14] E. Winer,et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Fumoleau,et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[17] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[18] Ludovic Ferrer,et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.